“CD Diagnostics focus is to provide physicians with analytical tools that enable them to make informed decisions that will improve patient outcomes. We will bring these analytical tools to market through corporate partnerships.”
The success of CD Diagnostics is built on our strategy of combining our GMP manufacturing, regulatory expertise, and immunoassay development with corporate partnering. Working with partners who need to develop and manufacture assays is a central tenant of our business plan – at CD Diagnostics, we consider ourselves experts in providing risk free development by performance based milestones to deliver to clients all of their assay needs, whether that be the discovery of a novel biomarker or simply the GMP production of an established product. Our CLIA laboratory enables companies to have rapid entry of critical tests for drug submissions or product entry. We provide quality and expertise equivalent to any large company at substantially lower prices. CD Diagnostics is a leader in the development and manufacture of diagnostics. Through our first corporate partnership with Zimmer we have made a significant impact in the rapid and accurate diagnosis of infection through the introduction of Synovasure. We have recently completed a new agreement in which we will develop a companion diagnostic to monitor the drug delivery and efficacy of a treatment for osteoarthritis. In addition to our R&D and manufacturing capabilities, this project will also utilize our unique access to tissue specimens that are sourced due to our extensive network of clinical relationships providing samples through ongoing IRB’s.
CD Diagnostics offers custom companion diagnostic development programs to complement pharmaceutical drug development and other targeted therapies. The use of companion diagnostics significantly improves patient outcomes by yielding more effective personalized therapies thereby reducing the overall cost of care.